Group 1 - The core point of the news is that Taiankang's stock experienced a decline of 2.09% on January 22, with a trading volume of 150 million yuan, indicating a potential concern in market sentiment [1] - On January 22, Taiankang had a financing buy-in amount of 22.96 million yuan and a net financing buy of 6.63 million yuan, with a total financing and securities balance of 976 million yuan, which is high compared to historical levels [1] - The company’s financing balance of 974 million yuan accounts for 7.19% of its circulating market value, exceeding the 80th percentile of the past year, indicating a high level of leverage [1] Group 2 - As of September 30, Taiankang had 12,000 shareholders, an increase of 9.32% from the previous period, while the average circulating shares per person decreased by 8.53% to 25,381 shares [2] - For the period from January to September 2025, Taiankang reported a revenue of 526 million yuan, a year-on-year decrease of 8.13%, and a net profit attributable to shareholders of 31.41 million yuan, down 73% year-on-year [2] - Since its A-share listing, Taiankang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [2]

CKBA作为一种全新靶点（First-in-Class，靶向ACC1/MFE-2）的免疫调节剂，并非传统的强效免疫抑制 剂，其核心作用在于抑制CD8+T细胞向Tc1及Tc17分化，下调IFN-γ和IL-17的表达，从而改善皮肤区域 免疫环境，有效阻止"白斑"扩增；而NB-UVB则可直接激活黑素干细胞，促进其分化为成熟黑素细胞并 产生黑素。 白癜风作为一种慢性自身免疫性疾病，以黑色素细胞功能性丧失导致的皮肤色素脱失为特征，全球患病 率达0.5%至2.0%，严重影响患者的容貌外观与生活质量。其中，儿童群体面临着更为严峻的挑战，儿 童白癜风患者约占总患者数的32%至40%。 然而，目前全球范围内尚无获批用于儿童白癜风治疗的产品，临床需求亟待满足。泰恩康表示，本次儿 童白癜风Ⅱ期临床试验申请获批后，公司将快速推进儿童白癜风Ⅱ期临床试验，争取CKBA乳膏获批成 为首个治疗2岁至12岁儿童白癜风的1类创新药，填补儿童白癜风诊疗空白。 本报讯 （记者王镜茹）1月22日晚，广东泰恩康医药股份有限公司（以下简称"泰恩康"）披露，其控股 子公司江苏博创园生物医药科技有限公司（以下简称"博创园"）收到国家药品监督管理局签发的《药物 ...

Core Viewpoint - The company Tianenkang (301263) announced that its subsidiary, Bochuangyuan, has received approval from the National Medical Products Administration for a clinical trial of CKBA cream in children aged 2 to 12 with non-segmental vitiligo [1] Group 1 - The clinical trial is a multi-center, randomized, double-blind, placebo-controlled Phase II study [1] - The study will evaluate the safety, efficacy, and pharmacokinetic characteristics of CKBA cream combined with narrowband ultraviolet B (NB-UVB) therapy [1] - The trial specifically targets participants who are children aged 2 years and older [1]

每经AI快讯，泰恩康发布公告称，2026年1月21日至2026年1月22日期间，泰恩康接受大成基金等投资 者调研，公司董事长、总经理郑汉杰先生，董事、副总经理兼董事会秘书李挺先生参与接待，并回答了 投资者提出的问题。 （记者 曾健辉） 每经头条（nbdtoutiao）——地方国资开始"抄底"法拍房！单价六七千元"扫货"广州南沙区超60套房 源，同小区二手房挂牌均价逾2万元 ...

Group 1: Clinical Research and Development - The company has initiated a Phase II clinical trial for CKBA cream for pediatric vitiligo, with the application accepted by the National Medical Products Administration in November 2025 [2][3]. - The exploratory study included 30 pediatric patients aged 2-12 years, showing a significant improvement in VASI scores with a 56.53% change in the treatment group compared to a 16.67% change in the control group (P=0.0029) [3]. - The Phase II clinical trial is expected to begin patient enrollment in Q2 2026, with a goal to complete it by mid-2027 [4]. Group 2: Market Potential and Demand - There are currently no approved drugs for pediatric vitiligo (ages 2-12) globally, indicating a significant unmet clinical need [5]. - The estimated market size for pediatric vitiligo treatment in China exceeds 100 billion CNY, with annual treatment costs ranging from 15,000 to 20,000 CNY per patient [6]. - CKBA is expected to achieve annual peak sales exceeding 5 billion CNY once approved for pediatric use [6]. Group 3: Additional Clinical Developments - The company has completed Phase II trials for CKBA in adult vitiligo and plans to optimize the Phase III trial protocol, with an application expected in Q1 2026 [7]. - CKBA is also being developed for other indications, including rosacea and Alzheimer's disease, with clinical trials for rosacea expected to start in Q1 2026 [7]. Group 4: Business Growth and Future Plans - The company anticipates significant revenue growth in 2026 and explosive growth in 2027, driven by the approval of several core products [8]. - Key products expected to be approved include a combination capsule of finasteride and tadalafil, and a lidocaine and prilocaine aerosol, among others [8].

证券代码：301263 证券简称：泰恩康 公告编号：2026-004 广东泰恩康医药股份有限公司 关于控股子公司 CKBA 乳膏申报儿童白癜风 获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于 2025 年 11 月 20 日 在巨潮资讯网（http://www.cninfo.com.cn）披露了《关于控股子公司 CKBA 乳 膏申报儿童白癜风临床试验取得受理通知书的公告》（公告编号：2025-076）。 近日，公司控股子公司江苏博创园生物医药科技有限公司（以下简称"博创 园"）收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意博 创园提交的 CKBA 乳膏联合窄谱中波紫外线（以下简称"NB-UVB"）在 2-12 岁（含 2 岁）儿童非节段型白癜风受试者中的安全耐受性、疗效和药代动力学 特征的多中心、随机、双盲、安慰剂对照 II 期临床研究申请。现将相关情况公 告如下： 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 19 日受理的 C ...

Group 1 - The company, 泰恩康 (301263), announced the release of share pledges by its controlling shareholders, 郑汉杰 and 孙伟文 [1] - 郑汉杰 released 4 million shares, while 孙伟文 released 2.5 million shares, totaling 6.5 million shares [1] - The released shares account for 1.53% of the company's total share capital [1]

证券代码：301263 证券简称：泰恩康 公告编号：2026-003 广东泰恩康医药股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于近日收到公司控股股东、 实际控制人郑汉杰先生、孙伟文女士的通知，获悉其所持有的公司部分股份办理 了解除质押的手续，具体情况如下： 注：本公告除特别说明外，数值保留 2 位小数，数据尾差为计算时四舍五入所致。 二、股东股份累计质押情况 截至本公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | | | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 名称 | 持股数量 （股） | 持股 比例 | 累计被质押 股份数量 | 持股份 | 总股本 | 已质押股份 限售和冻结、 | 占已质 押股份 | 未质押股 份限售和 | 占未质 押股份 | | | | （% ...

（记者 王瀚黎） 每经头条（nbdtoutiao）——重磅数据公布：回升！专访徐洪才："内卷式竞争"得到一定缓解，下一 步"补收入"可形成良性循环 每经AI快讯，泰恩康1月21日晚间发布公告称，截至本公告日，郑汉杰累计质押股数为3550万股，占其 所持股份比例为40.17%。孙伟文累计质押股数为2177万股，占其所持股份比例为32.88%。 ...

| 权益类证券大宗交易(协议交易) | | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-21 | 301263 | 泰恩康 | 30.40 | 10.00 | 304.00 | 国联民生证券股份 | 国联民生证券股份 | | | | | | | | 有限公司上海虹口 | 有限公司上海分公 | | | | | | | | 区杨树浦路证券营 | ロ | | | | | | | | 41 58 | | 1月21日，泰恩康大宗交易成交10万股，成交额304万元，占当日总成交额的1.28%，成交价30.4元，较 市场收盘价32.54元折价6.58%。 ...